Form D · Pharmaceuticals
Sarkana Pharma, Inc.
Wilmington, DE · CIK 0001845313
Offering snapshot reported Feb 17, 2021 · SEC filing
- Reported sold
- $1.58M Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 21, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 17, 2021 | Initial | $1,579,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-389612
This offering was made in exchange for certain licensing rights to investor's proprietary compound, which rights were estimated to be valued at $1,579,000.
Source: Form D, filed Feb 17, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Cipriano | Executive |
| Caroline Fortier | Executive |
| Luc Marengere | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1000 N. West St., Suite 1200
Wilmington, DE, 19801
Wilmington, DE, 19801